Articular Joint-Simulating Mechanical Load Activates Endogenous TGF-β in a Highly Cellularized Bioadhesive Hydrogel for Cartilage Repair

2019 ◽  
Vol 48 (1) ◽  
pp. 210-221 ◽  
Author(s):  
Peter Behrendt ◽  
Yann Ladner ◽  
Martin James Stoddart ◽  
Sebastian Lippross ◽  
Mauro Alini ◽  
...  

Background: The treatment of osteochondral defects (OCDs) constitutes a major problem for orthopaedic surgeons. The altered mechanics and the cell types, with associated soluble factors derived from the exposed subchondral bone, are likely responsible for the mechanically and structurally inferior articular cartilage subsequently obtained as a repair tissue. There is therefore an unmet clinical need for bioresponsive biomaterials that allow cell delivery, reduce cell infiltration from the bone marrow, and support chondrogenesis in the presence of joint mechanical loading. Purpose: To develop a cell-laden injectable biomaterial, with bioadhesive properties, low cell invasion, and good mechanoresilience, in which simulated joint loading could induce tissue maturation through the production and activation of transforming growth factor beta 1 (TGF-β1). Study Design: Controlled laboratory study. Methods: Human bone marrow–derived mesenchymal stromal/stem cells were encapsulated in tyramine-modified hyaluronic acid (HA-Tyr) hydrogels, with crosslinking initiated by the addition of horseradish peroxidase (HRP) and various concentrations of hydrogen peroxide (H2O2; 0.3-2 mM). Cytocompatibility and biomechanical and adhesive properties were analyzed by live/dead staining, rheology, and push-out test, respectively. For multiaxial loading, cell-laden hydrogels were subjected to 10% compression superimposed onto a 0.5-N preload and shear loading (±25°) at 1 Hz for 1 hour per day and 5 times a week for 4 weeks. TGF-β1 production and activation were measured by enzyme-linked immunosorbent assay (ELISA). Results: The viscoelastic properties of the cell-laden HA-Tyr hydrogels, as crosslinked with different ratios of HRP and H2O2, were demonstrated for a range of cell densities and HRP/H2O2 concentrations. In the absence of serum supplementation, cell invasion into HA-Tyr hydrogels was minimal to absent. The bonding strength of HA-Tyr to articular cartilage compared favorably with clinically used fibrin gel. Conclusion: HA-Tyr hydrogels can be mechanically conditioned to induce activation of endogenous TGF-b1 produced by the embedded cells. HA-Tyr hydrogels function as cell carriers supporting biomechanically induced production and activation of TGF-β1 and as bioadhesive materials with low cell invasion, suggesting that they hold promise as a novel biomaterial for OCD repair strategies. Clinical Relevance: Leveraging physiological joint mechanics to support chondrogenic graft maturation in an optimized mechanosensitive hydrogel in the absence of exogenous growth factors is of highest interest for OCD repair.

2022 ◽  
Vol 20 (2) ◽  
pp. 275-280
Author(s):  
Lei Ji ◽  
Xue Zhong ◽  
Xingxing Xia ◽  
Wei Yu ◽  
Yuping Qin

Purpose: To investigate the protective role of syringaresinol in a rat model of diabetic nephropathy (DN). Methods: Streptozotocin was injected intraperitoneally into rats to establish the diabetic model. Streptozotocin-induced rats were orally administered syringaresinol, and pathological changes in kidneys were assessed using hematoxylin and eosin staining. Enzyme-linked immunosorbent assay (ELISA) was used to determine kidney injury indicators, 24-h urine proteins, blood urea nitrogen (BUN), and serum creatinine (SCR). Blood glucose was measured using a blood glucose meter, while levels of malonaldehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-PX) in kidney were also measured using ELISA. Results: Pathological changes in the kidneys were observed in rats post-streptozotocin treatment. Administration of syringaresinol reduced the lesion degree, with improved pathological morphology in kidney. Syringaresinol administration significantly attenuated streptozotocin-increased levels of BUN, SCR, 24-h urine protein, and blood glucose (p < 0.01). Streptozotocin-induced oxidative stress, shown by enhanced MDA level and reduced levels of SOD, CAT, and GSH-PX, was reversed in rat kidneys following syringaresinol administration. However, the expression levels of nuclear factor erythropoietin- 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) proteins decreased, while transforming growth factor-beta 1 (TGF-β1) and signal transducer and transcriptional modulator (Smad) 2/3/7 proteins increased in rats post-streptozotocin treatment. Syringaresinol administration reversed the effects of streptozotocin on protein expression of Nrf2, HO-1, TGF-β1, and Smad 2/3/7. Conclusion: Syringaresinol exerted a protective effect against DN through activation of Nrf2 and inactivation of TGF-β1/Smad pathways. Thus, the compound can potentially be developed for management of diabetic nephropathy.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1398-1398
Author(s):  
Stephen Bartelmez ◽  
Francis W Ruscetti ◽  
Patrick Iversen ◽  
Ashay Bhatwadekar ◽  
Maria Grant

Abstract Previously, we demonstrated that a transient blockade of endogenous transforming growth factor-beta type 1 (TGF-β1) in murine and human HSC accelerates bone marrow engraftment while dramatically reducing the number of HSC needed for long-term reconstitution. CD34+ cells give rise to endothelial progenitor cells (EPC) and have been shown to participate in the repair of damaged vasculature. CXCR4 is the receptor for stromal derived factor (SDF-1), a chemoattractant released by ischemic tissue that guides EPCs to damaged sites. In this study, we examined levels of TGF- β1 mRNA in CD34+ blood and bone marrow (BM) cells of diabetic and non diabetic individuals. We also treated CD34+ cells of diabetic and nondiabetic origin with antisense phosphorodiamidate morpholino oligomers (PMOs) to TGF-β1 and examined surface expression of CXCR-4, migratory response to SDF-1 as well as in vivo reparative function in a model of retinal ischemic injury. Our results show that CD34+ EPC from the blood of diabetic patients are markedly defective in their ability to repair damaged retinal vessels compared to control cells in contrast to CD34+ cells from the diabetic BM. Diabetic CD34+EPC from blood express elevated levels of TGF-β1 mRNA and have a blunted migratory response to SDF-1 compared to controls (p&lt;0.05 and p&lt;0.01 respectively). Transient (2–4 days) blockade of endogenous TGF-β1 using PMOs to TGF- β1 in diabetic CD34+/EPC increases CXCR-4 expression in these cells, enhances their migratory prowess and restores their ability to repair damaged retinal vessels. This approach is an enhanced autologous stem cell therapy based on a well studied, rapid and reversible modification of bone marrow CD34+EPCs derived from the diabetic patient.


2018 ◽  
Vol 7 (11) ◽  
pp. 587-594 ◽  
Author(s):  
R-K. Zhang ◽  
G-W. Li ◽  
C. Zeng ◽  
C-X. Lin ◽  
L-S. Huang ◽  
...  

Objectives The role of mechanical stress and transforming growth factor beta 1 (TGF-β1) is important in the initiation and progression of osteoarthritis (OA). However, the underlying molecular mechanisms are not clearly known. Methods In this study, TGF-β1 from osteoclasts and knee joints were analyzed using a co-cultured cell model and an OA rat model, respectively. Five patients with a femoral neck fracture (four female and one male, mean 73.4 years (68 to 79)) were recruited between January 2015 and December 2015. Results showed that TGF-β1 was significantly upregulated in osteoclasts by cyclic loading in a time- and dose-dependent mode. The osteoclasts were subjected to cyclic loading before being co-cultured with chondrocytes for 24 hours. Results A significant decrease in the survival rate of co-cultured chondrocytes was found. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) assay demonstrated that mechanical stress-induced apoptosis occurred significantly in co-cultured chondrocytes but administration of the TGF-β1 receptor inhibitor, SB-505124, can significantly reverse these effects. Abdominal administration of SB-505124 can attenuate markedly articular cartilage degradation in OA rats. Conclusion Mechanical stress-induced overexpression of TGF-β1 from osteoclasts is responsible for chondrocyte apoptosis and cartilage degeneration in OA. Administration of a TGF-β1 inhibitor can inhibit articular cartilage degradation. Cite this article: R-K. Zhang, G-W. Li, C. Zeng, C-X. Lin, L-S. Huang, G-X. Huang, C. Zhao, S-Y. Feng, H. Fang. Mechanical stress contributes to osteoarthritis development through the activation of transforming growth factor beta 1 (TGF-β1). Bone Joint Res 2018;7:587–594. DOI: 10.1302/2046-3758.711.BJR-2018-0057.R1.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4621-4621
Author(s):  
Davoud Mohtat ◽  
Thomas Moulton ◽  
M. Catherine Driscoll ◽  
Robert P Woroniecki

Abstract Abstract 4621 Renal failure is one of the major complications of sickle cell disease (SCD), affecting 5-18% of the patients. Microalbuminuria (MA), which has a prevalence of 26.5% in all children with SCD, is used as a marker of preclinical glomerular damage and renal disease progression. However, measuring MA alone may miss renal damage involving tubular proteins. We hypothesize that sickle cell nephropathy subjects will have increased urinary excretion of Transforming Growth Factor Beta-1 (TGF β1) and Neutrophil Gelatinase–Associated Lipocalin (NGAL) as compared to age-matched controls (CTR). We also hypothesize that urinary excretion of these proteins will be associated with severity of anemia in SCD. Enzyme-Linked Immunosorbent Assay (ELISA) kits were used to detect urinary excretion of TGF β1/NGAL, and corrected to urine creatinine. Mean age, gender, and race were not statistically different among the groups. Urinary excretion of TGF β1 was significantly higher in SCD subjects (26.4 pg/mg Cr +/-1.5) vs. CTR (14.9 pg/mg Cr +/-2.4), (p<0.00001). There was no difference in urinary NGAL between the SCD subjects vs. CTR. SCD patients with hemoglobin less than 9gm/dl had higher urinary TGF β1 than SCD patients with milder anemia (p=0.002). Urinary TGF β1 was lower in SCD patients on hydroxyurea (23.61+/-2.6), vs. those who were (27.69+/-1.8), p=0.08. Surprisingly, there were no correlation between urinary TGF β1 and urinary microalbumin or estimated glomerular function, indicating that microalbuminuria and serum creatinine are poor measures of renal injury in SCD patients. Our data suggests that urinary TGF β1 may serve as a urinary biomarker to monitor the progression of renal disease in SCD. This assumption needs to be tested prospectively. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 49 (5) ◽  
pp. 64-71
Author(s):  
Shan Liu ◽  
Jianjun Li ◽  
Liya Hu

Objective: Bronchopneumonia is a common respiratory infection disease and is the leading cause of hospitalization in children under 5 years of age. Inflammation is the primary response caused by bronchopneumonia. But the detailed underlying mechanism of inflammation in bronchopneumonia remains unclear. Therefore, this study focused on studying the effect of miR-216a-5p on inflammation induced by bronchopneumonia and investigate the potential mechanism underlying it.Methods: Human bronchial epithelial cells (BEAS-2B) were stimulated using lipopolysaccha-rides (LPS) to trigger bronchopneumonia in vitro. The production of interleukin (IL)-1β, IL-6, and Tumor necrosis factor (TNF)-α was measured using the enzyme-linked immunosorbent assay. The luciferase assay was conducted to explore the relationship between miR-216a-5p and TGFBR2. Quantitative real-time polymerase chain reaction and western blot were used to detect the gene expression.Results: miR-216a-5p gene expression decreased in BEAS-2B cells stimulated by LPS. Overexpression of miR-216a-5p suppressed the elevated levels of IL-1β, IL-6, and TNF-α induced by LPS. Transforming growth factor-beta receptor 2 (TGFBR2) proved to be a direct target of miR-216a-5p, and they negatively modulated TGFBR2 expression. In addition, overexpression of miR-216a-5p inhibited LPS-induced protein levels of TGFBR2,transforming growth factor (TGF)-β1, and phosphorylation of SMAD family member 2 (smad2),. This ectopic expression of miR-216a-5p was restored by overexpressed TGFBR2.Conclusion: miR-216a-5p was decreased in LPS-stimulated BEAS-2B cells. Overexpressed miR-216a-5p suppressed LPS-induced inflammation in BEAS-2B cells by inhibition of TGF-β1 signal-ing via down-regulating TGFBR2. miR-216a-5p may be a valuable target for anti-inflammation treatment in bronchopneumonia.


2020 ◽  
Author(s):  
Tayyebe Khamoushi ◽  
Moslem Ahmadi ◽  
Mohammad Ali-Hassanzadeh ◽  
Maryam Zare ◽  
Fateme Hesampour ◽  
...  

Abstract Objective Placenta accreta is a pregnancy-related disorder with extreme trophoblast invasion and the adherence of the placenta to the uterine wall. This study aimed to investigate the serum level of transforming growth factor-beta 1 (TGF-β1) and interleukin (IL)-35 in patients with placenta accreta. Methods Thirty-one women with placenta accreta and 57 healthy pregnant women were enrolled. The serum levels of TGF-β1 and IL-35 were measured using the enzyme-linked immunosorbent assay method. Results The serum levels of both TGF-β and IL-35 were significantly higher in the placenta accreta group compared with the group of healthy women (1082.48 pg/mL vs 497.33 pg/mL and 4541.14 pg/mL vs 1306.04 pg/mL; P &lt;.001, respectively). Moreover, the level of TGF-β1 positively correlated with the IL-35 level but other factors such as age, gestations, live births, and abortions did not correlate with IL-35 and TGF-β1 levels. Conclusion The serum levels of IL-35 and TGF-β1 may contribute to the pathogenesis of placenta accreta and could be considered as potential targets in clinical and diagnostic approaches.


2019 ◽  
Vol 26 (2) ◽  
pp. 169-175 ◽  
Author(s):  
Natalia Pertseva ◽  
Inna Borysova ◽  
Daria Chub

Abstract Background and aims: Transforming growth factor-beta 1 (TGF-β1) and vascular adhesion molecule 1 (VCAM-1) have been proposed as promising biomarkers for multiple diseases. TGF-β1 and VCAM-1 are reported to be associated with diabetic kidney disease (DKD) and end stage renal disease in patients with type 1 and type 2 diabetes mellitus (T1DM and T2DM). Material and methods: The aim of this study was to investigate the expression of circulating TGF-β1 and VCAM-1 and to assess their potential as a blood-based biomarker for DKD in T1DM and T2DM patients. Results:. The study included 124 participants: 66 patients with T1DM, 58 with T2DM and 20 healthy controls. The diabetic patients were classified according to the estimated glomerular filtration rate (eGFR). First group - eGFR ≥90ml/min/1.73 m2 (n=39), second group eGFR 89-60 ml/min/1.73m2 (n=45), and third group eGFR 59-45 ml/min/1.73m2 (n=40). Enzyme-linked immunosorbent assay for the quantitative detection of was used to evaluate blood TGF-β1 and VCAM-1 expression. It was found that there were higher TGF-β1 and VCAM-1 in all diabetic patients compared with healthy controls (P<0.05). TGF- β1 and VCAM-1 were higher in group with eGFR ≥90ml/min/1.73 m2 and gradually increased in the groups with eGFR89-60 ml/min/1.73m2 and eGFR 59-45 ml/min/1.73m2. TGF- β1 and VCAM-1 were less in T1DM, than T2DM in all study groups. Regression analysis revealed reverse associations between TGF- β1, VCAM-1 and eGFR (P<0.05). TGF- β1 and VCAM-1 correlated positively with albuminuria and negatively with renal function. Conclusion: In discriminating overall patients from healthy subjects, ROC analysis revealed areas under the curve (AUCs) of 1,0 for TGF- β1 for T1DM and T2DM, VCAM-1 0,866 for T1DM, 0,923 for T2DM (P<0.001). The results suggested that blood-based TGF- β1 and VCAM-1 may serve as potential biomarkers for early detection of DKD.


Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3502
Author(s):  
Michael H. Bourne ◽  
Theodore J. Kottom ◽  
Deanne M. Hebrink ◽  
Malay Choudhury ◽  
Edward B. Leof ◽  
...  

Idiopathic pulmonary fibrosis (IPF) remains an intractably fatal disorder, despite the recent advent of anti-fibrotic medication. Successful treatment of IPF, like many chronic diseases, may benefit from the concurrent use of multiple agents that exhibit synergistic benefit. In this light, phosphodiesterase type 5 inhibitors (PDE5-Is), have been studied in IPF primarily for their established pulmonary vascular effects. However, recent data suggest certain PDE5-Is, particularly vardenafil, may also reduce transforming growth factor beta 1 (TGF-β1) activation and extracellular matrix (ECM) accumulation, making them a potential target for therapy for IPF. We evaluated fibroblast TGF-β1-driven extracellular matrix (ECM) generation and signaling as well as epithelial mesenchymal transformation (EMT) with pretreatment using the PDE5-I vardenafil. In addition, combinations of vardenafil and nintedanib were evaluated for synergistic suppression of EMC using a fibronectin enzyme-linked immunosorbent assay (ELISA). Finally, the effects of vardenafil on fibrosis were investigated in a bleomycin mouse model. Our findings demonstrate that vardenafil suppresses ECM generation alone and also exhibits significant synergistic suppression of ECM in combination with nintedanib in vitro. Interestingly, vardenafil was shown to improve fibrosis markers and increase survival in bleomycin-treated mice. Vardenafil may represent a potential treatment for IPF alone or in combination with nintedanib. However, additional studies will be required.


2017 ◽  
Vol 3 (1) ◽  
pp. 15 ◽  
Author(s):  
Hasret Ecevit ◽  
Kubra Gunduz ◽  
Nilufer Bilgic ◽  
Muzeyyen Izmirli ◽  
Bulent Gogebakan

<p>Thymoquinone, one of the essential oil in the structure of cumin, is used for alternative therapy for many diseases from past to present. It was shown to have anti-carcinogenic and anti-inflammatory effects, as well as positive effects on fibrosis. However, there is no study on the effect of thymoquinone on cancer and fibrosis mechanism in bronchial epithelium cell line BEAS-2B. In our study, the effect of thymoquinone on cell viability and transforming growth factor-beta 1 (TGF-β1) level, which has an important role in the regulation of many biological processes including cancer and fibrosis-associated signal transduction, was evaluated. BEAS-2B cells were exposed to thymoquinone at 0–80 μmol/L concentrations for 24-, 48- and 72-hour durations. Cell viability was evaluated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. TGF-β1 level was determined with enzyme-linked immunosorbent assay (ELISA) method from the collected supernatant. Cell viability was found to be increased at all concentrations and durations (10–80 μmol/L; 24, 48 and 72 h) according to the control group (0 μmol/L; thymoquinone in ethanol) (p &lt; 0.0001). Moreover, thymoquinone was found to increase the level of TGF-β1 only at 80 μmol/L concentration and 24-hour exposure period (0 μmol/L, 53.41 ± 18.44 pgr/ml TGF-β1; 80 μmol/L, 174.5 ± 80.03 pgr/ml TGF-β1). As a result, thymoquinone was found to increase cell proliferation and encourage TGF-β1 release.</p>


Sign in / Sign up

Export Citation Format

Share Document